Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer

Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Piccart-Gebhart, Martine
Pritchard, Kathleen
McCullough, Ann A.E.
Dolci, Stella
McFadden, Eleanor
Holmes, Andrew A.P.
Tonghua, Liu
Eidtmann, Holger
Dinh, Phuong
Di Cosimo, Serena
Harbeck, Nadia
Holmes, Eileen
Tjulandin, Sergei
Im, Young Hyuck
Huang, Chiun Sheng
Diéras, Véronique
Hillman, David D.W.
Wolff, Antonio A.C.
Jackisch, Christian
Lang, Istvan
Untch, Michael
Smith, Ian
Baselga, José
Boyle, Frances
Xu, Binghe
Gomez, Henry
Suter, Thomas
Gelber, Richard R.D.
Perez, Edith A
de Azambuja, Evandro
Dueck, Amylou A.C.
Viale, Giuseppe
Zujewski, Jo Anne
Goldhirsch, Aron
Armour, Alison

April 2016

Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growt...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

Targeted treatment of advanced and metastatic breast cancer with lapatinib

Brendan Corkery
Norma O&amp
John Crown

September 2008

Brendan Corkery1,2, Norma O&rsquo;Donovan2, John Crown1,21St. Vincent&rsquo;s University Hos...

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

Powles, T
Huddart, RA
Elliott, T
Sarker, S-J
Ackerman, C
Jones, R
Hussain, S
Crabb, S
Jagdev, S
Chester, J
Hilman, S
Beresford, M
Macdonald, G
Santhanam, S
Frew, JA
Stockdale, A
Hughes, S
Berney, D
Chowdhury, S

January 2017

Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in hu...

Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer

Powles, Thomas
Huddart, Robert A.
Elliott, Tony
Sarker, Shah-Jalal
Ackerman, Charlotte
Jones, Robert
Hussain, Syed
Crabb, Simon
Jagdev, Satinder
Chester, John
Hilman, Serena
Beresford, Mark
Macdonald, Graham
Santhanam, Sundar
Frew, John A.
Stockdale, Andrew
Hughes, Simon
Berney, Daniel
Chowdhury, Simon

January 2017

Purpose: To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in h...

Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer

Powles, Thomas
Huddart, Robert A.
Elliott, Tony
Sarker, Shah-Jalal
Ackerman, Charlotte
Jones, Robert
Hussain, Syed
Crabb, Simon
Jagdev, Satinder
Chester, John
Hilman, Serena
Beresford, Mark
Macdonald, Graham
Sundar, Santhanam
Frew, John A.
Stockdale, Andrew
Hughes, Simon
Berney, Daniel
Chowdhury, Simon

January 2017

Purpose: The purpose of this trial was to establish if maintenance lapatinib after first-line chemot...

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

Cerbone, L.
Sternberg, C.N.
Sengelov, L.
Agerbaek, M.
Herpen, C.M.L. van
Marreaud, S.
Collette, S.
Zhang, J.
Daugaard, G.

January 2016

BACKGROUND/OBJECTIVE: Lapatinib is a potent HER1 and HER2 inhibitor. Gemcitabine-cisplatin (GC) is a...

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma : a randomized phase III clinical trial

Ravaud, Alain
Hawkins, Robert
Gardner, Jason P.
von der Maase, Hans
Zantl, Niko
Harper, Peter
Rolland, Frédéric
Audhuy, Bruno
Machiels, Jean-Pascal
Pétavy, Frank
Gore, Martin
Schöffski, Patrick
El-Hariry, Iman

January 2008

Purpose Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor (EGFR)/human...

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

Wülfing, Christian
Machiels, Jean-Pascal
Richel, Dirk J.
Grimm, Marc-Oliver
Treiber, Uwe
De Groot, Marco R.
Beuzeboc, Philippe
Parikh, Roma
Pétavy, Frank
El-Hariry, Iman A.

January 2009

BACKGROUND: The treatment of recurrent transitional cell carcinoma (TCC) remains an unmet clinical n...

Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)

Moehler, Markus
Schad, Arno
Maderer, Annett
Atasoy, Ajlan
Mauer, Murielle E
Caballero, Carmela
Thomaidis, Thomas
John, Jestinah M Mahachie
Lang, Istvan
Van Cutsem, Eric
Freire, Joao
Lutz, Manfred P
Roth, Arnaud

October 2018

PURPOSE: HER2-targeted therapy with trastuzumab and (CF/X) prolonged overall survival (OS) in metast...

Comparison of Global versus Epidermal Growth Factor Receptor Pathway Profiling for Prediction of Lapatinib Sensitivity in Bladder Cancer

Havaleshko, Dmytro M.
Smith, Steven Christopher
Cho, HyungJun
Cheon, Sooyoung
Owens, Charles R.
Lee, Jae K.
Liotta, Lance A.
Espina, Virginia
Wulfkuhle, Julia D.
Petricoin, Emanuel F.
Theodorescu, Dan

November 2009

Chemotherapy for metastatic bladder cancer is rarely curative. The recently developed small molecule...

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial

정현철

October 2017

PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in pa...

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

Harrington, K.
Temam, S.
Mehanna, H.
D'Cruz, A.
Jain, M.
D'Onofrio, I.
Manikhas, G.
Horvath, Z.
Sun, Y.
Dietzsch, S.
Dubinsky, P.
Holeckova, P.
El-Hariry, I.
Franklin, N.
Biswas-Baldwin, N.
Legenne, P.
Wissel, P.
Netherway, T.
Farrell, J.
Ellis, C.
Wang-Silvanto, J.
Amonkar, M.
Ahmed, N.
Santillana, S.
Bourhis, J.

January 2015

PURPOSE: This multicenter phase III study evaluated the efficacy and safety of lapatinib, an epiderm...

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

Vergote, Ignace
Jimeno, Antonio
Joly, Florence
Katsaros, Dionyssios
Coens, Corneel
Despierre, Evelyn
Marth, Christian
Hall, Marcia
Steer, Christopher B
Colombo, Nicoletta
Lesoin, Anne
Casado, Antonio
Reinthaller, Alexander
Green, John
Buck, Martin
Ray-Coquard, Isabelle
Ferrero, Annamaria
Favier, Laure
Reed, Nick Simon
Curé, Hervé
Pujade-Lauraine, Eric

February 2014

This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGF...

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)

Lin, Nancy U.
Guo, Hao
Yap, Jeffrey T.
Mayer, Ingrid A.
Falkson, Carla I.
Hobday, Timothy J.
Dees, E. Claire
Richardson, Andrea L.
Nanda, Rita
Rimawi, Mothaffar F.
Ryabin, Nicole
Najita, Julie S.
Barry, William T.
Arteaga, Carlos L.
Wolff, Antonio C.
Krop, Ian E.
Winer, Eric P.
Van den Abbeele, Annick D.

January 2015

Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, huma...

Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Piccart-Gebhart, Martine
Pritchard, Kathleen
McCullough, Ann A.E.
Dolci, Stella
McFadden, Eleanor
Holmes, Andrew A.P.
Tonghua, Liu
Eidtmann, Holger
Dinh, Phuong
Di Cosimo, Serena
Harbeck, Nadia
Holmes, Eileen
Tjulandin, Sergei
Im, Young Hyuck
Huang, Chiun Sheng
Diéras, Véronique
Hillman, David D.W.
Wolff, Antonio A.C.
Jackisch, Christian
Lang, Istvan
Untch, Michael
Smith, Ian
Baselga, José
Boyle, Frances
Xu, Binghe
Gomez, Henry
Suter, Thomas
Gelber, Richard R.D.
Perez, Edith A
de Azambuja, Evandro
Dueck, Amylou A.C.
Viale, Giuseppe
Zujewski, Jo Anne
Goldhirsch, Aron
Armour, Alison

April 2016

Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growt...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

Targeted treatment of advanced and metastatic breast cancer with lapatinib

Brendan Corkery
Norma O&amp
John Crown

September 2008

Brendan Corkery1,2, Norma O&rsquo;Donovan2, John Crown1,21St. Vincent&rsquo;s University Hos...

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

Powles, T
Huddart, RA
Elliott, T
Sarker, S-J
Ackerman, C
Jones, R
Hussain, S
Crabb, S
Jagdev, S
Chester, J
Hilman, S
Beresford, M
Macdonald, G
Santhanam, S
Frew, JA
Stockdale, A
Hughes, S
Berney, D
Chowdhury, S

January 2017

Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in hu...

Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer

Powles, Thomas
Huddart, Robert A.
Elliott, Tony
Sarker, Shah-Jalal
Ackerman, Charlotte
Jones, Robert
Hussain, Syed
Crabb, Simon
Jagdev, Satinder
Chester, John
Hilman, Serena
Beresford, Mark
Macdonald, Graham
Santhanam, Sundar
Frew, John A.
Stockdale, Andrew
Hughes, Simon
Berney, Daniel
Chowdhury, Simon

January 2017

Purpose: To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in h...

Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer

Powles, Thomas
Huddart, Robert A.
Elliott, Tony
Sarker, Shah-Jalal
Ackerman, Charlotte
Jones, Robert
Hussain, Syed
Crabb, Simon
Jagdev, Satinder
Chester, John
Hilman, Serena
Beresford, Mark
Macdonald, Graham
Sundar, Santhanam
Frew, John A.
Stockdale, Andrew
Hughes, Simon
Berney, Daniel
Chowdhury, Simon

January 2017

Purpose: The purpose of this trial was to establish if maintenance lapatinib after first-line chemot...

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

Cerbone, L.
Sternberg, C.N.
Sengelov, L.
Agerbaek, M.
Herpen, C.M.L. van
Marreaud, S.
Collette, S.
Zhang, J.
Daugaard, G.

January 2016

BACKGROUND/OBJECTIVE: Lapatinib is a potent HER1 and HER2 inhibitor. Gemcitabine-cisplatin (GC) is a...

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma : a randomized phase III clinical trial

Ravaud, Alain
Hawkins, Robert
Gardner, Jason P.
von der Maase, Hans
Zantl, Niko
Harper, Peter
Rolland, Frédéric
Audhuy, Bruno
Machiels, Jean-Pascal
Pétavy, Frank
Gore, Martin
Schöffski, Patrick
El-Hariry, Iman

January 2008

Purpose Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor (EGFR)/human...

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

Wülfing, Christian
Machiels, Jean-Pascal
Richel, Dirk J.
Grimm, Marc-Oliver
Treiber, Uwe
De Groot, Marco R.
Beuzeboc, Philippe
Parikh, Roma
Pétavy, Frank
El-Hariry, Iman A.

January 2009

BACKGROUND: The treatment of recurrent transitional cell carcinoma (TCC) remains an unmet clinical n...

Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)

Moehler, Markus
Schad, Arno
Maderer, Annett
Atasoy, Ajlan
Mauer, Murielle E
Caballero, Carmela
Thomaidis, Thomas
John, Jestinah M Mahachie
Lang, Istvan
Van Cutsem, Eric
Freire, Joao
Lutz, Manfred P
Roth, Arnaud

October 2018

PURPOSE: HER2-targeted therapy with trastuzumab and (CF/X) prolonged overall survival (OS) in metast...

Comparison of Global versus Epidermal Growth Factor Receptor Pathway Profiling for Prediction of Lapatinib Sensitivity in Bladder Cancer

Havaleshko, Dmytro M.
Smith, Steven Christopher
Cho, HyungJun
Cheon, Sooyoung
Owens, Charles R.
Lee, Jae K.
Liotta, Lance A.
Espina, Virginia
Wulfkuhle, Julia D.
Petricoin, Emanuel F.
Theodorescu, Dan

November 2009

Chemotherapy for metastatic bladder cancer is rarely curative. The recently developed small molecule...

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial

정현철

October 2017

PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in pa...

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

Harrington, K.
Temam, S.
Mehanna, H.
D'Cruz, A.
Jain, M.
D'Onofrio, I.
Manikhas, G.
Horvath, Z.
Sun, Y.
Dietzsch, S.
Dubinsky, P.
Holeckova, P.
El-Hariry, I.
Franklin, N.
Biswas-Baldwin, N.
Legenne, P.
Wissel, P.
Netherway, T.
Farrell, J.
Ellis, C.
Wang-Silvanto, J.
Amonkar, M.
Ahmed, N.
Santillana, S.
Bourhis, J.

January 2015

PURPOSE: This multicenter phase III study evaluated the efficacy and safety of lapatinib, an epiderm...

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

Vergote, Ignace
Jimeno, Antonio
Joly, Florence
Katsaros, Dionyssios
Coens, Corneel
Despierre, Evelyn
Marth, Christian
Hall, Marcia
Steer, Christopher B
Colombo, Nicoletta
Lesoin, Anne
Casado, Antonio
Reinthaller, Alexander
Green, John
Buck, Martin
Ray-Coquard, Isabelle
Ferrero, Annamaria
Favier, Laure
Reed, Nick Simon
Curé, Hervé
Pujade-Lauraine, Eric

February 2014

This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGF...

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)

Lin, Nancy U.
Guo, Hao
Yap, Jeffrey T.
Mayer, Ingrid A.
Falkson, Carla I.
Hobday, Timothy J.
Dees, E. Claire
Richardson, Andrea L.
Nanda, Rita
Rimawi, Mothaffar F.
Ryabin, Nicole
Najita, Julie S.
Barry, William T.
Arteaga, Carlos L.
Wolff, Antonio C.
Krop, Ian E.
Winer, Eric P.
Van den Abbeele, Annick D.

January 2015

Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, huma...

Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Piccart-Gebhart, Martine
Pritchard, Kathleen
McCullough, Ann A.E.
Dolci, Stella
McFadden, Eleanor
Holmes, Andrew A.P.
Tonghua, Liu
Eidtmann, Holger
Dinh, Phuong
Di Cosimo, Serena
Harbeck, Nadia
Holmes, Eileen
Tjulandin, Sergei
Im, Young Hyuck
Huang, Chiun Sheng
Diéras, Véronique
Hillman, David D.W.
Wolff, Antonio A.C.
Jackisch, Christian
Lang, Istvan
Untch, Michael
Smith, Ian
Baselga, José
Boyle, Frances
Xu, Binghe
Gomez, Henry
Suter, Thomas
Gelber, Richard R.D.
Perez, Edith A
de Azambuja, Evandro
Dueck, Amylou A.C.
Viale, Giuseppe
Zujewski, Jo Anne
Goldhirsch, Aron
Armour, Alison

April 2016

Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growt...

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial

A. Decensi
M. Puntoni
G. Pruneri
A. Guerrieri-Gonzaga
M. Lazzeroni
D. Serrano
D. Macis
H. Johansson
O. Pala
A. Luini
P. Veronesi
V. Galimberti
M.C. Dotti
G. Viale
B. Bonanni

August 2011

Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor l...

Targeted treatment of advanced and metastatic breast cancer with lapatinib

Brendan Corkery
Norma O&amp
John Crown

September 2008

Brendan Corkery1,2, Norma O&rsquo;Donovan2, John Crown1,21St. Vincent&rsquo;s University Hos...

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer

Abstract

Extracted data

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer

Abstract

Extracted data

Related items

Related items